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Background: On average, older adults have more medical morbidities and consume a greater number of
prescribed medications than their younger counterparts. However, the independent impact of greater
medication use on symptom burden is not clear.
Objective: To determine to what extent there is: (1) an association between medical morbidity and
symptom burden; and/or (2) an association between medication use and symptom burden.
Materials and methods: We performed a cross-sectional study, including one-on-one surveys of patients
and medical record reviews, at a Veterans’ Affairs primary care clinic in Connecticut, involving 159
community-dwelling males age >65 years, who were seen at routine appointments during the 5-month
study period. The most commonly reported symptoms associated with adverse drug events were
considered, and severity of symptoms was reported according to a Likert scale. Symptom burden was
calculated as the sum of “severe and very severe” symptoms across all symptom categories. Linear
regression and Chi-square analyses were performed to assess the bivariate associations between
symptom burden and medications and between symptom burden and medical morbidities.
Results: On average, participants had 2.6  1.4 medical morbidities, were prescribed 7.9  2.8 medica-
tions, and reported 0.70  1.2 severe or very severe symptoms. Linear regression analysis demonstrated a
direct association between medical morbidities and symptom burden (slope ¼ 0.38, r2 ¼ 0.17, p< 0.0001)
and a weaker association between medication use and symptom burden (slope ¼ 0.11, r2 ¼ 0.06,
p ¼ 0.002). When considered in a multiple regression model, medical morbidity continued to be a
signiﬁcant predictor of symptom burden (p < 0.0001), but the number of medications was no longer
predictive (p ¼ 0.52).
Conclusion: Medical morbidity contributes signiﬁcantly to symptom burden, and use of additional
medications does not allay or contribute to this effect.
Copyright  2013, Asia Paciﬁc League of Clinical Gerontology & Geriatrics. Published by Elsevier Taiwan
LLC. Open access under CC BY-NC-ND license. 1. Introduction
Quality of Life (QOL) is a health outcome that is valued by many
older adults.1 In fact, a recent study demonstrated that only 25% of
older patients rated “being kept alive” as more important thanedicine, Massachusetts Gen-
02114, USA.
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 other goals of care, including symptom reduction and pain reduc-
tion. QOL, as a health outcome, can be most broadly deﬁned as a
multidimensional concept that refers to an individual’s overall life
satisfaction and total well-being.2 More speciﬁcally, the Center for
Health Promotion at the University of Toronto has divided the QOL
outcome into three broad domains: well-being (including physical,
psychological, and spiritual components), belonging (including
physical, social, and community components), and becoming
(including growth, practical, and leisure components).3ublished by Elsevier Taiwan LLC. Open access under CC BY-NC-ND license.
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collectively inﬂuence QOL in older individuals, symptom burden is
one contributing factor that has consistently been shown to nega-
tively impact QOL scores.4e9 A symptom can be conceptualized as
multidimensional in nature with components that include fre-
quency, severity, and distress.10 The resultant effect of these di-
mensions across all symptoms experienced by the patient can be
referred to as symptomburden. Symptom burden is an entitywhich
encompasses both the severity of the symptoms and the patient’s
perception of the impact of all of his/her symptoms. Because
symptomburden signiﬁcantly inﬂuences QOL, it is important toﬁnd
ways to reduce symptom burden in the older adult population.
It has been suggested that medical morbidities in older patients
are largely responsible for the occurrence of symptoms, many of
which are managed through the use of pharmacotherapy.11
Although one of the objectives of pharmacotherapy is to alleviate
symptoms, considerable evidence has demonstrated that increased
medication use also results in higher rates of adverse drug reactions
(ADRs).12 Though these events are often considered to be secondary
side effects, studies indicate that older patients regard these
adverse events to be as important as the beneﬁcial effects of
medication.1,4 Consequently, it is not clear whether older adults
who take multiple medications achieve net improvement or
detriment in symptom burden with each additional medication, or
whether there is a threshold at which medication use becomes
more harmful than beneﬁcial in the reduction of symptom burden.
Given the elevated rates of both medical morbidities and medica-
tion use by older patients, it is clinically relevant to explore the
impact that each independently has on symptom burden.
Prior studies assessing the impact of medical morbidities on
symptom burden among community-dwelling individuals are
limited in number, but they have consistently demonstrated a direct
relationship.8 However, only one of these studies controlled for the
number of prescribed medications as a confounder, and this study
was limited to patients who had recently started dialysis.13 There are
even fewer published studies exploring the association between
medication use and symptomburden, and the results of these studies
are conﬂicting. A study of older Native Americans demonstrated an
inverse relationship betweenmedication use and health-related QOL
(HRQOL),14 although this study did not control for several medical
morbidities. Another study demonstrated a linear relationship be-
tweennumberofmedicationsandtwospeciﬁc clinicalmanifestations
e weight loss and impaired balance15 e after adjusting for comor-
bidities. By contrast, a survey of a rural elderly population demon-
strated no association between medication use and QOL scores.16
For an older population that may value the relief of symptom
burden as much as survival or disease prevention, it is important to
establish the impact that both diseases and themedications used to
treat these diseases have on symptom burden. The primary ob-
jectives of this study were to determine the independent associa-
tions between medical morbidities and symptom burden and
between medication use and symptom burden in an older
community-dwelling population.
2. Materials and methods
2.1. Study design
A cross-sectional study based on patient surveys and review of
electronic medical records.
2.2. Participants
Participants in this study were enrolled between August 2007
and December 2007. Participants were eligible for the study if theywere 65 years of age, enrolled in a primary care clinic in the VA
Connecticut Healthcare System, and able to provide written
informed consent in English. Exclusion criteria were: (1) residence
at a long term care facility at the time of data collection; and (2)
inability to complete the patient interview. A total of 170 partici-
pants who met eligibility criteria for the parent study were
approached at regular outpatient appointments; 166 (98%) agreed
to participate and provided informed consent. Seven of the par-
ticipants (4%) were female, and they were subsequently excluded
from the analysis, as the study was unlikely to be powered to yield
statistically signiﬁcant information regarding gender. Primary data
was collected for 159 participants through one-on-one patient in-
terviews conducted by trained research assistants in the clinical
ofﬁce setting and through review of electronic medical records. The
Institutional Review Board of the VA Connecticut Healthcare Sys-
tem approved the study.
2.3. Symptom assessment
On the date of a participant’s ofﬁce visit, symptom occurrence
and severity were evaluated through a patient-directed question-
naire and subsequent electronic chart review conducted by a
blinded researcher. Participants were asked if they regularly
experienced 18 symptoms (difﬁculty sleeping, change in mood,
depression, nausea, diarrhea, constipation, decreased appetite,
dizziness, imbalance, headache, fatigue, confusion, muscular aches,
rash, falls, weight loss, urinary incontinence, and difﬁculty
thinking) without providing a deﬁnition or description of any
symptoms. The symptoms selected focused on the cardiovascular,
gastrointestinal, and nervous systems and encompass the most
common adverse drug effects experienced by older adults as re-
ported in prior studies.12,17e20 For all symptoms experienced
regularly, participants were asked to rate “how bothersome” they
found the symptom to be on a Likert scale from zero to four, where
zero was “not at all” and four was “severely”.
A review of patient charts up to 1 year prior to the interview,
including outpatient clinic notes, Emergency Department notes,
discharge summaries, and telephone notes, was conducted to
assess for any additional symptom documentation by health care
providers. If a symptom was noted by a clinician in the medical
record, the researcher searched for further evidence that a clinician
linked this symptom to a medication(s). If a symptom-medication
relationship was noted, evidence for a medication change related
to the symptom was further documented.
Symptom data was modiﬁed for this study to facilitate data
analysis. Five symptoms (urinary incontinence, falls, diarrhea, rash,
and weight loss) were excluded, because strictly deﬁned they
represented objective clinical signs, rather than symptoms. One
symptom (headache) was excluded due to the low rate of patients
reporting at any severity level (<15%). Clinically similar symptoms
were combined into related symptom groups, as it was not clear
that patients were able to accurately differentiate these symptoms
from one another. Related symptom groups included change in
mood and depression, difﬁculty thinking and confusion, dizziness
and imbalance, and nausea and decreased appetite. The ﬁnal
analysis included eight symptoms/symptom groups, including
change in mood/depression, difﬁculty thinking/confusion, dizzi-
ness/imbalance, nausea/decreased appetite, fatigue, constipation,
aches and pains, and difﬁculty sleeping.
To obtain a measure of overall symptom burden for each
participant, a composite variable was created, indicating the total
number of severe or very severe (three or four on the Likert scale,
respectively) symptoms experienced across the eight symptom
groups. We considered symptoms with a bothersome rating >2 to
be clinically signiﬁcant, because it was thought that patients who
Table 1
Baseline characteristics of study participants.
Characteristics n ¼ 159
Age (y) 76  6
Education (y) 12  3
MMSE 27  3
Male 159 (100)
Race/ethnicity
Caucasian 145 (91)
African American 13 (8)
Hispanic 1 (<1)
Medical morbidity
Hypertension 117 (74)
Diabetes mellitus 64 (40)
Arthritis 49 (31)
Myocardial infarction 31 (20)
Peripheral vascular disease 28 (18)
COPD 26 (16)
Cancer (all types) 26 (16)
Heart failure 17 (11)
Depression 16 (10)
Stroke 14 (9)
Diabetes with organ dysfunction 6 (4)
Dementia 5 (3)
Peptic ulcer disease 4 (3)
Liver disease 1 (<1)
Renal disease 1 (<1)
Lymphoma 1 (<1)
Cirrhosis 1 (<1)
Cancer (metastatic) 1 (<1)
Number of medical morbidities
0 4 (3)
1 38 (24)
2 40 (25)
3 35 (22)
4 28 (18)
5 12 (8)
6 2 (1)
2.6  1.4
Number of medications
<6 40 (25)
6e9 76 (48)
>9 43 (27)
7.9  2.8
Reported symptom burden
0 106 (67)
1 22 (14)
2 14 (9)
3 12 (8)
4 2 (1)
5 2 (1)
6 0
7 1 (<1)
Mean, median, SD 0.70, 0, 1.2
Data are presented as mean  SD or n (%), unless otherwise indicated.
COPD ¼ chronic obstructive pulmonary disease; MMSE ¼ Mini Mental State
Examination.
Table 2
Frequency of symptoms at any severity level and at severe/very severe levels.
Symptom group (%) Any
severity, n ¼ 159
Severe/very
severe, n ¼ 159
Dizziness/imbalance 57 16
Change in mood/depression 47 10
Fatigue 43 7
Difﬁculty sleeping 42 11
Muscle aches 42 12
Difﬁculty thinking/confusion 32 5
Constipation 32 4
Nausea/decreased appetite 23 5
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be willing to modify their medication regimens as a result. Each
signiﬁcant symptom added one point to the symptom burden,
regardless of whether the symptom was rated as severe or very
severe.
2.4. Medication assessment
Information regarding prescribed medications was obtained
from the list of activemedications in the VA Connecticut Healthcare
System electronic medical record. Vitamins/supplements were
included, but topical ointments and as needed medications were
excluded from analysis.
2.5. Medical morbidities assessment
Information regarding medical morbidities was assessed
through a patient questionnaire and electronic chart review of
patient problem lists. Assessment included 15 Charlson comor-
bidities (diabetes mellitus, diabetes with organ dysfunction,
arthritis, myocardial infarction, peripheral vascular disease, chronic
obstructive pulmonary disease, heart failure, stroke, dementia,
peptic ulcer disease, liver disease, renal disease, lymphoma,
cirrhosis, and metastatic malignancy) and three non-Charlson
comorbidities [hypertension, depression, and cancer (all types)].
2.6. Statistical analysis
Baseline characteristics for the study populations were sum-
marized by mean  standard deviation for continuous outcomes
and by count and proportion (%), unless otherwise described. Linear
regression analyses were performed to assess the bivariate asso-
ciations between symptom burden and medications and between
symptom burden and medical morbidity. Bivariate analyses were
also performed to identify potential confounders of symptom
burden, including age, education level, mental status, and number
of physician visits in the last year. Multiple linear regression anal-
ysis was applied to assess the concurrent associations between
symptom burden, medications, and medical morbidity. A result
with p < 0.05 was considered statistically signiﬁcant. Data analysis
was performed with SAS version 9.1 (SAS Institute Inc., Cary, NC,
USA).
3. Results
3.1. Description of participants
The sample was predominantly older individuals (mean  SD,
76  6 years), Caucasian (91%), high-school educated (12th
grade  3 years), with multiple medical morbidities (2.6  1.4
morbidities), and high rates of polypharmacy (7.9  2.8 medica-
tions; Table 1). Over 30% of the participants had hypertension,
diabetes mellitus, arthritis, and myocardial infarction. The most
commonly prescribed medication classes included 3-hydroxy-3-
methylglutaryl-coenzyme (HMG-CoA) reductase inhibitors (re-
ported by 81%), angiotensin-converting-enzyme (ACE)-inhibitors
(67%), beta-blockers (58%), and diuretics (52%).
Study participants reported the regular occurrence and severity
of eight symptoms/symptomgroups (Table 2). More than 40% of the
participants reported dizziness/imbalance, change in mood/
depression, fatigue, difﬁculty sleeping, or muscle aches at any
severity level. Regarding severe/very severe symptoms, at least 10%
reported dizziness/imbalance, change in mood/depression, difﬁ-
culty sleeping, and muscle aches.Based on the results of symptom reporting, symptom burden
(including only severe and very severe symptoms, as detailed
above) was calculated for each patient. Symptom burden for par-
ticipants ranged from zero to seven. Mean symptom burden was
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zero (Table 1).Fig. 2. Symptom burden versus number of medications.3.2. Variable analysis
Using simple linear regression analysis, a linear association be-
tween medical morbidities and symptom burden was demon-
strated (slope ¼ 0.38, r2 ¼ 0.17, p < 0.0001; Fig. 1). Similarly, a
weaker linear association between number of prescribed medica-
tions and symptom burden was observed (slope ¼ 0.11, r2 ¼ 0.06,
p ¼ 0.002) (Fig. 2). When assessing for potential confounders, there
was no signiﬁcant association between symptom burden and age,
education level, or mental status. Only the number of physician
visits in the last year was identiﬁed as a confounder of symptom
burden (p < 0.0001), and this variable was included in the multiple
regression model detailed below.
To estimate the independent effects that medication use and
medical morbidities have on symptom burden, a multiple linear
regression analysis was performed. Using this model, the effect of
number of medical morbidities on symptom burden remained sta-
tistically signiﬁcant (slope¼0.33, p<0.0001); however, the number
of prescribed medications was no longer a signiﬁcant independent
predictor of symptom burden (p ¼ 0.52), suggesting that physician
visits as a confounder may have been driving the association be-
tween symptom burden and number of prescribed medications.
To determine whether the model was complicated by multi-
collinearity, variance inﬂation factor (VIF) of the full model was
calculated, which included age, years of education, mental status,
number of patient visits, number of medications, and number of
comorbid conditions. The observed VIF values ranged from 1.03 to
1.25, which demonstrated that multicollinearity did not impact the
regression analysis. The possibility of confounding was further
investigated through Chi-square analyses, which independently
considered the association between: (1) symptom burden and
number of medications; and (2) symptom burden and number of
medications per number of physician visits. For this analysis,
symptom burden was considered a binary variable (symptom
burden ¼ 0, symptom burden >0). Number of medications was
classiﬁed as <6, 6e9, and >9. Neither of these Chi-square analyses
demonstrated a statistically signiﬁcant association between
symptom burden and medication use. These ﬁndings demonstrate
that controlling for number of physician visits would not signiﬁ-
cantly impact the association between symptom burden and
medication use and that our initial regression model is not inﬂu-
enced by physician visits as a confounder.
Because a high proportion of participants reported a symptom
burden score of zero, Chi-square analyses were also conducted
considering symptom burden as a binary variable (symptom
burden ¼ 0, symptom burden >0). Chi-square analysis assessingFig. 1. Symptom burden versus number of medical morbidities.the association between symptom burden and number of medical
morbidities (medical morbidity <3, medical morbidity >2) yielded
a statistically signiﬁcant result (p ¼ 9.56E-08). Chi-square analysis
assessing the association between symptom burden and number of
medications (1e5, 6e9, and > 9 medications) did not produce a
statistically signiﬁcant result (p ¼ 0.208). These results corroborate
those obtained through regression analysis.4. Discussion
In this cohort of community-dwelling older male adults, we
demonstrated a positive association between medical morbidity
and symptom burden using linear regression and Chi-square
analysis. All of the participants reported at least one medical
morbidity and were taking one or more medications. Dizziness/
imbalance was reported most frequently, and few participants re-
ported severe/very severe symptoms. We did not demonstrate an
independent association between medication use and symptom
burden with either linear regression or Chi-square analysis.
The demonstrated association between cumulative medical
morbidity and symptom burden is clinically reasonable and has been
reported in previous studies.21e23 The ﬁndings of this study expand
upon current knowledgebydemonstrating that the impact ofmedical
morbidityonsymptomburden is independent of theextent of contact
with thehealthcare system(e.g., thenumberofphysicianvisits). Thus,
the association betweenmedicalmorbidities and symptom burden is
likely explained, in part, by the cumulative contribution ofmorbidity-
related symptoms.Our study furtherdeﬁnes the relationshipbetween
medical morbidity and symptom burden by showing that this asso-
ciation is not signiﬁcantly weakened or strengthened by controlling
for the number of prescribed medications.
Our study did not ﬁnd an independent association between
medication use and symptom burden, suggesting that medication
use does not result in a signiﬁcant net change in symptom burden.
This ﬁnding supports the results of a similar study conducted on an
older Native American population.14 These ﬁndings can be
explained in at least two ways. One possibility is that the use of
medication does not alleviate, improve, worsen, or cause any
symptoms. Alternatively, it is conceivable that alleviation of the
targeted symptoms may provide a net beneﬁt in symptom burden
that is equal to the net detriment conferred by drugedrug in-
teractions or other medication side effects. For example, adding a
beta blocker to a medication regimen may improve symptoms of
angina and palpitations, but it may concurrently cause dizziness
and fatigue, resulting in no net change in overall symptom burden.
Our investigation has several limitations. First, the cross-
sectional design of our study precludes the determination of cau-
sality of the associations we observed; thus, it cannot be concluded
whether the increase in symptom burden results directly from the
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clinical perspective to reason that medical conditions do result in
the development of symptoms and contribute to overall symptom
burden. A second potential limitation of this study is recall bias.
Because the symptoms reported by patients were not necessarily
present at the time of the interview, it is conceivable that in-
dividuals might have experienced other symptoms that they did
not report. However, because we only included severe and very
severe symptoms in our symptom burden calculations, it is more
likely that participants’ recall of symptoms was accurate, as a per-
son is more likely to remember symptoms of greater severity. Given
the demographics of our study participants, our results may not be
generalizable to women, minorities, or persons who do not reside
in the community. In addition, we did not report on the effects that
other potential confounding variables may have on symptom
burden, including health habits and social supports, both of which
have been recognized as impacting symptom burden in older per-
sons.8 Finally, because the symptoms considered in this study are
those most commonly associated with adverse medication effects,
this study may overestimate the negative effects and underesti-
mate the positive effects of medication use.
The results of this study are strengthened by the use of a con-
servative estimation of symptom burden. Because our assessment
included only severe and very severe symptoms, it is conceivable
that patients may opt to reduce symptom burden even at the
expense of disease prevention or prolonged survival.
In conclusion, this study investigated the association thatmedical
morbidity and medication use have with symptom burden. Medical
morbiditieswere associated stronglywith symptomburden, and the
use of additional medications did not allay this effect. This suggests
that for patientswhohave speciﬁed the reduction of symptoms as an
important health outcome, consideration of treatment modalities
other than medication prescribing may be particularly beneﬁcial.
Given the low adverse-effect proﬁle of non-pharmacologic in-
terventions, such as physical therapy, massage, and meditation,
physicians may consider counseling patients regarding these stra-
tegies. The development of other methods for calculating the risk
beneﬁt ratio for medication use may further enhance clinical man-
agement of this population.15,24 Additional research is necessary to
determine whether particular medication classes, medical morbid-
ities, or symptoms drive trends in symptom burden, so that therapy,
pharmacologic and otherwise, can be further tailored to improve
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